-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RY-103 in Neurodegenerative Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RY-103 in Neurodegenerative Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RY-103 in Neurodegenerative Diseases Drug Details: RY-103 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RY-103 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RY-103 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RY-103 in Alzheimer's Disease Drug Details: RY-103 is under development for the...
-
Product Insights
Acute Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Acute Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RY-103 in Neurodegenerative Diseases
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RY-103 in Neurodegenerative Diseases Drug Details: RY-103 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HH-006 in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HH-006 in Hepatitis D report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HH-006 in Hepatitis DDrug Details:HH-006 is under development for the treatment of Hepatitis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AST-004 in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AST-004 in Traumatic Brain Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AST-004 in Traumatic Brain Injury Drug Details: AST-004 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AST-004 in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AST-004 in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AST-004 in Acute Ischemic Stroke Drug Details: AST-004 is under...